KRKA, d. d., Novo mesto
Decision of the Court of Appeal in esomeprazole case in the Great Britain
Krka, d.d., Novo mesto (hereafter referred to as Krka) is informing the public that Krka has received the decision of the Court of Appeal in London refused the appeal filed by AstraZeneca AB, Sweden and AstraZeneca UK Limited (hereinafter collectively referred to as AstraZeneca) which requested that the Appeals Court set aside the decision of the High Court of Justice, Patents Court in London which awarded to Krka damages and legal costs in the total amount of slightly less than EUR 21 million for losses Krka has suffered because it was injuncted to sell esomeprazole between mid-2010 to mid-2011 because alleged infringement of AstraZeneca's patent EP 1 020 461.
AstraZeneca can request a leave to appeal at the Supreme Court. Krka has formed provisions for the assigned amount that will be released when the decision is final and all legal means are exhausted
Krka published the announcement considering esomeprazole litigation in the Great Britain on 7 April 2014.
Krka, d. d., Novo mesto